Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

ConditionGlioblastoma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCity of Hope Medical Center

About this trial

This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can be found in cerebrospinal fluid (CSF), which is the fluid that surrounds the brain and spinal cord. Collecting CSF can be difficult and expensive, especially if samples are needed frequently to track these particles over time. Tear fluid is easier to collect than spinal fluid. If tears are found to contain similar tumor-related particles, changes in the tumor may be tracked by studying the particles found in tear fluid.

Eligibility criteria

Qualifiers

Adults (age ≥ 18)

Male and female

All racial and ethnic groups

Pathologically-proven diagnosis of GBM or healthy volunteers

Disqualifiers

Active ocular infection or inflammation

Recent ocular surgery (within 3 months)

Chronic dry eyes

Known allergy or hypersensitivity to topical anesthetics

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Biospecimen Collection
  • Electronic Health Record Review
  • Questionnaire Administration

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators

City of Hope Medical Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator